This post was originally published on this site
The U.S. life sciences company submitted the concessions to the European Commission last week.
They consist of royalty-free global licences to rivals of next-generation sequencing technology and equipment and a pledge not to pursue any patent litigation against BGI in Europe, the sources said.
The EU antitrust watchdog had sought feedback from rivals and customers, giving them until Tuesday to do so, they said.
